Adjunctive Sertraline for the treatment of HIV-associated Cryptococcal Meningitis (360G-Wellcome-105436_Z_14_Z)
This is a phase III randomized trial to evaluate the early fungicidal activity of sertraline when added to standard amphotericin-based therapy for cryptococcal meningitis. The primary objective is to determine whether adjunctive sertraline will improve survival through 18-weeks as compared to standard therapy alone. Secondary objectives include comparing the adjunctive sertraline groups and control group for early fungicidal activity, pharmacokinetics, microbiologic susceptibilities, safety, incidence of immune reconstitution syndrome or relapse, and potential cost-benefit. Cryptococcal diagnosis will be made via CSF cryptococcal antigen (CRAG) at time of lumbar puncture (LP) with confirmation by CSF culture. After informed consent, subjects who meet eligibility requirements will be able to enter study. Phase III Design: Subjects will be randomized to standard induction therapy with masked placebo or sertraline at either 200mg or 400mg/day doses. We will use a permutated block randomization in a 1:1:1 allocation (n=160 per arm). CSF from the LPs at diagnosis, day 3, day 7, day 10, and day 14 will be collected for quantitative cryptococcal CSF cultures. Quantitative cultures will be used to calculate the rate of clearance (early fungicidal activity) over 14-days and compared between study arms. Subjects will be followed for up to 18 weeks to assess for secondary endpoints. An 18-week duration of study participation is chosen as ~90% of the mortality in the first 5 years after cryptococcal meningitis occurs in the first 18 weeks.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2014-06-03T00:00:00+00:00 |
| Internal ID | 105436/Z/14/Z |
| Planned Dates: End Date | 2017-06-30T00:00:00+00:00 |
| Planned Dates: Start Date | 2014-07-01T00:00:00+00:00 |
| Amount Awarded | 159411 |
| Financial Year | 2013/14 |
| Lead Applicant | Prof David Meya |
| Grant Programme: Title | Joint Global Health Trials Award |
| Partnership Name | Joint Global Health Trials |
| Applicant Surname | Meya |
| Approval Committee | Joint Global Health Trials Committee |
| Recipient Org: Country | Uganda |
| Recipient Org: City | Kampala |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | Yes |
| Total amount including partnership funding | 159411 |